Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
$0.35
-0.7%
$0.40
$0.22
$1.30
$7.70M1.08477,605 shs1.03 million shs
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
$3.03
-0.7%
$3.87
$2.96
$9.84
$14.30M0.51141,780 shs23,453 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.50
-2.5%
$3.64
$2.57
$6.77
$22.18M0.575,901 shs2,276 shs
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
$1.59
+4.6%
$0.81
$0.24
$3.98
$52.78M0.741.63 million shs425,453 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
0.00%+0.43%-11.28%-0.03%-68.18%
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
0.00%-1.94%-15.58%-36.88%-62.68%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00%-2.78%-7.16%+1.19%-45.14%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
0.00%-3.64%+161.86%+127.08%-47.35%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
$0.35
-0.7%
$0.40
$0.22
$1.30
$7.70M1.08477,605 shs1.03 million shs
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
$3.03
-0.7%
$3.87
$2.96
$9.84
$14.30M0.51141,780 shs23,453 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.50
-2.5%
$3.64
$2.57
$6.77
$22.18M0.575,901 shs2,276 shs
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
$1.59
+4.6%
$0.81
$0.24
$3.98
$52.78M0.741.63 million shs425,453 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
0.00%+0.43%-11.28%-0.03%-68.18%
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
0.00%-1.94%-15.58%-36.88%-62.68%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00%-2.78%-7.16%+1.19%-45.14%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
0.00%-3.64%+161.86%+127.08%-47.35%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
3.00
Buy$8.002,185.71% Upside
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
3.00
Buy$26.50774.59% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
2.25
Hold$5.00214.47% Upside

Current Analyst Ratings Breakdown

Latest ADIL, NAII, CMMB, and RLMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2025
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$10.00 ➝ $25.00
8/20/2025
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
N/AN/AN/AN/A$0.64 per shareN/A
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
N/AN/AN/AN/A$2.87 per shareN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.19N/AN/A$13.32 per share0.26
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/AN/AN/AN/A$1.18 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
-$13.20M-$1.05N/AN/AN/AN/A-191.31%-153.59%11/12/2025 (Estimated)
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
-$13.94M-$2.36N/AN/AN/AN/A-94.71%-76.53%11/13/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%9/26/2025 (Estimated)
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$79.98M-$2.22N/AN/AN/AN/A-223.17%-180.41%11/6/2025 (Estimated)

Latest ADIL, NAII, CMMB, and RLMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
-$0.80-$0.36+$0.44-$0.09N/AN/A
8/13/2025Q2 2025
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
-$0.22-$0.18+$0.04-$0.18N/AN/A
8/7/2025Q2 2025
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$0.25-$0.30-$0.05-$0.30N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
N/AN/AN/AN/AN/A
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
N/A
5.02
5.02
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
N/A
7.42
7.42
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/A
4.11
4.11
CompanyEmployeesShares OutstandingFree FloatOptionable
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
2021.83 million20.90 millionNo Data
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
204.71 million4.15 millionNot Optionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
1033.19 million26.32 millionOptionable

Recent News About These Companies

Relmada Issues Mid-Year CEO Letter to Shareholders
Relmada Therapeutics Reports Promising Phase 2 Study Results
RLMD Relmada Therapeutics, Inc. - Seeking Alpha
Relmada Therapeutics, Inc. (RLMD) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adial Pharmaceuticals stock logo

Adial Pharmaceuticals NASDAQ:ADIL

$0.35 0.00 (-0.74%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$0.35 +0.00 (+1.14%)
As of 09/12/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Chemomab Therapeutics stock logo

Chemomab Therapeutics NASDAQ:CMMB

$3.03 -0.02 (-0.66%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$3.02 0.00 (-0.17%)
As of 09/12/2025 05:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.55 -0.04 (-1.11%)
As of 09/12/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

Relmada Therapeutics stock logo

Relmada Therapeutics NASDAQ:RLMD

$1.59 +0.07 (+4.61%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$1.53 -0.06 (-3.77%)
As of 09/12/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.